Brief: Eli Lilly To Sign $2 Bln Deal For AI Drug Development With Hong Kong Biotech Insilico Medicine - FT
29/03/2026 12:06
March 29 (Reuters) - ELI LILLY TO SIGN $2BN DEAL FOR AI DRUG DEVELOPMENT WITH HONG KONG BIOTECH INSILICO MEDICINE - FT LILLY WILL ACQUIRE EXCLUSIVE RIGHTS TO SELL A GLP-1 DRUG FOR DIABETES FROM INSILICO MEDICINE - FT Source text: https://tinyurl.com/yrh4f2hz Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7